Comparative Pharmacology
Head-to-head clinical analysis: DYAZIDE versus HYDRO D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYAZIDE versus HYDRO D.
DYAZIDE vs HYDRO-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
25-100 mg orally once daily in the morning.
None Documented
None Documented
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic